Abstract: Malignant melanoma is an aggressive form of cancer which is highly resistant to chemotherapy. We have previously found that gambogic acid (GA), a kind of polyprenylated xanthone, exhibits an antitumour role in melanoma. The study was designed to investigate novel mechanisms of the antitumour effect of GA in melanoma cells and implanted nude mice. Gambogic acid significantly decreased cell viability, increased apoptosis and reduced migration and invasion in A375 cells. In addition, cisplatin-induced cytotoxicity in both A375 and A375/CDDP cells was increased by GA. The expression of miR-199a-3p was increased by GA in A375 cells and implanted tumours, and inhibition of miR-199a-3p significantly prevented GA-induced effect on cell viability, apoptosis, migration, invasion and cisplatin sensitivity in A375 cells. miR-199a-3p mimics reduced tumour weight and volume in vivo and decreased cell viability, increased apoptosis and reduced migration and invasion in vitro. miR199a-3p expression was decreased in melanoma tissues and cells, as compared with their controls. miR-199a-3p possessed a potential binding site in the 3 0 -UTR of zinc finger E-box binding homeobox (ZEB1). ZEB1 expression was increased in melanoma tissues and cells, as compared with their controls. ZEB1 and miR-199a-3p expression was negatively correlated in melanoma tissues. The expression of ZEB1 was decreased by GA in A375 cells and implanted tumours, and up-regulation of ZEB1 significantly prevented GA-induced effect on cell viability, apoptosis, migration, invasion and cisplatin sensitivity. Down-regulation of ZEB1 reduced tumour weight and volume in vivo and decreased cell viability, increased apoptosis and reduced migration and invasion in vitro. We identified the important roles of miR-199a-3p and ZEB1 in melanoma and elucidated the tumour suppressor function of miR-199a-3p through inhibition of ZEB1. The results highlight the importance of miR-199a-3p-ZEB1 signalling in antitumour effect of GA in malignant melanoma and provide novel targets for the chemotherapy of melanoma.
Malignant melanoma is an aggressive form of cancer that derives from the transformation of melanocytes [1] . The incidence of melanoma has been rising faster than any other solid tumour [2] . In China, 20,000 new cases of melanoma are diagnosed each year [3] . Malignant melanoma is characterized by high metastatic potential, high resistance to chemotherapy and a poor survival rate. In recent years, researchers have made great endeavour to evaluate several chemo-and immune-based therapies for melanoma treatment in clinical trials. However, it is disappointing that most of those therapies had no significant benefits in melanoma patients [3] [4] [5] . Recently, the efficacy of BRAF inhibition and immune checkpoint blockade approaches has been shown in melanoma patients [4] . However, these measures fail to treat advanced melanoma [5] . Therefore, the need for a better understanding of melanoma development and progression and exploration of potential treatment options is unabated.
Gambogic acid (GA) is a naturally occurring polyprenylated xanthone mainly extracted from the traditional Chinese medicine herb Garcinia hanburyi Hook f. [6] . In China, GA has been widely used for homoeostasis, detoxification and antiinflammation for a long time [7] . In recent years, the antitumour effects of GA have been identified in various types of cancers, including hepatoma, lung, epithelial cervical, prostate, pancreatic and gastric cancer [8] . Multiple signalling pathways have been described for GA treatment of individual cancer cell lines [9] . Our results and literature have shown inhibitory effect of GA in malignant melanoma [10, 11] . However, the mechanism of antitumour effect of GA in melanoma is not completely understood.
MicroRNAs (miRNAs) are small and non-coding 21-to 25-bp RNA molecules which play key roles in post-transcriptional regulation of gene expression by binding to the 3 0 -UTR of targeted mRNA [12] . miRNAs can regulate the expression of genes associated with development, physiology and disease [13] . Evidence obtained from mouse [14] , goat and sheep [15] and alpaca [16, 17] has suggested that miRNAs are involved in hair colour determination by regulating melanogenesis. In the process of cell proliferation, transformation and tumorigenesis, miRNAs have been found to play essential roles [18] . Specifically, more and more evidence has identified that abnormal miRNA expression is required for the initiation and procession of tumours [19] [20] [21] . For melanoma, a battery of miRNAs has been found to be dysregulated [22] [23] [24] [25] .
In this study, we aimed to investigate the miRNA regulation that mediates GA-exhibited inhibition of malignant melanoma cell proliferation, metastasis and chemoresistance in vitro and in vivo.
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Materials and Methods
Patients and tissues. Twenty-one melanoma tissues and fifteen benign nevi tissues were collected from The Second Affiliated Hospital of Xi'an Jiaotong University. The use of these specimens was approved by the Ethics Committee of The Second Affiliated Hospital of Xi'an Jiaotong University. The samples were immediately frozen in liquid nitrogen for further determination. We obtained written informed consents from all of recipients enrolled. These patients did not receive any radiation or chemotherapy before operation. All tissue sections were reviewed by at least two experienced pathologists.
Cell culture. Human malignant melanoma cell lines A375, cisplatinresistant cell line A375/CDDP, WM35, SK-MEL-5 and SK-MEL-2 were obtained from American Type Culture Collection (Manassas, VA, USA) and were incubated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ ml penicillin and 100 U/ml streptomycin at 37°C in a 5% CO 2 atmosphere. Human epidermal melanocytes (HEMa-LP) were purchased from Invitrogen (Carlsbad, CA, USA) and were cultured in medium with HMGS-2 in a humidified atmosphere of 5% CO 2 at 37°C. A375 and A375/CDDP cells were treated by 1-10 lg/ml GA for 24 hr in serum-free medium.
Cells transfection. A375 or A375/CDDP cells were transfected with precursor miRNA (pre-hsa-miR-199a-3p, #PM11779) or inhibitor miRNA (anti-hsa-miR-199a-3p, #AM11779) at a concentration of 166 nM. Pre-miR miRNA Precursor Negative Control #1 (#AM17110) was used as a control. All these oligonucleotides were purchased from Life Technologies (Thermo Fisher Scientific, Inc.). Oligonucleotide transfection was performed using Lipofectamine 2000 according to the manufacturer's protocols. Lentiviral vector (LV)-mediated ZEB1 (LV-ZEB1) was ordered from Sigma (Sigma Aldrich, St. Louis, MO, USA) and then transfected using Lipofectamine 2000 into cells to overexpress ZEB1 expression. LV-shZEB1 was purchased from Santa Cruz Biotechnology and then transfected using Lipofectamine 2000 into cells to down-regulate ZEB1 expression.
Cell viability. Cell viability was evaluated using a Cell Counting Kit-8 (Beyotime Biotechnology, Shanghai, China). Cells were plated in 96-well plates at 1 9 10 3 per well and cultured at 37°C. After the experiment, 10 ll CCK8 solution was added and incubated for an additional 2 hr. Then, the absorbance at 450 nm was measured. The experiments were performed in triplicate.
Measurement of apoptosis.
Terminal deoxynucleotidyl transferasemediated dUTP nick-end labelling (TUNEL) assay (Roche, Basel, Switzerland) was conducted to determine apoptosis as previously described. After the treatment, cells were washed with phosphatebuffered saline (PBS), fixed in 4% paraformaldehyde and then incubated with 3% H 2 O 2 in methanol for 10 min. at room temperature to block endogenous peroxidase activity. Then, cells were incubated with TUNEL in an incubator at 37°C for 1 hr. After washing with PBS twice, FITC fluorescence was analysed using a cytometer (BD Biosciences, San Jose, CA, USA). Triplicate individual experiments were performed. Results were expressed as percentage of apoptotic cells.
Invasion and migration assays. The ability of migration was evaluated by wound healing assay. Briefly, cells were plated in a 6-well plate. Wounds were created with a 100-ll pipette tip on cells grown to 100% confluence. The detached cells were washed away with PBS. Cell migration was photographed under a light microscope (Olympus, Shinjuku-ku, Tokyo, Japan) at 24 hr after wounding. Results are shown as folds of migration. The ability of invasion was evaluated by transwell assay. Briefly, 1 9 10 5 cells were plated into the upper chambers in transwell inserts in a 24-well plate with transwell (8 mm pore size; Corning, New York, USA) coated with Matrigel free of serum (BD Biosciences). Medium containing 10% FBS was added into the lower chambers as a chemoattractant. Cells were incubated in an incubator at 37°C with 5% CO 2 for 48 hr, and then, the medium was removed and the upper surfaces were rinsed with PBS three times. Cells remaining in the upper chamber were removed with cotton buds, while cells that invaded the lower surfaces of the filters were fixed in 4% polyformaldehyde for 30 min., airdried and stained with 0.1% crystal violet for 10 min. Stained cells adhering to the lower surface of the membrane were counted by photographing six fields per membrane. Results are shown as folds of transwell cell numbers.
Real-time polymerase chain reaction. Total RNA was isolated from cells and tissues according to the manufacturer's instructions (TaKaRa, Dalian, China). RNA was quantified by spectrophotometry, and 500 ng RNA was reverse-transcribed to cDNA using a cDNA synthesis kit (TaKaRa). The samples were analysed by Real-time polymerase chain reaction (RT-PCR) using the BIORAD System for quantitative evaluation of RT-PCR. One microlitre of cDNA was amplified with SYBR Premix Ex Taq (TaKaRa). The amplification was performed on an Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), with a first step at 95°C for 3 min. and then 40 cycles with 95°C for 15 sec., 60°C for 5 sec. and 68°C for 30 sec. with a fluorescent reading at the end of this step. Primers used were as follows: miR-199a-3p forward, ÀDDCt method relative to the appropriate housekeeping gene.
Western blotting. After the experiment, cells or tumour tissues were lysed with cell lysis buffer (50 Mm Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10 mM NaF, 1 mM Na 3 VO 4 and protease inhibitor cocktail) on ice for 30 min. After centrifugation at 20,000 9 g for 20 min. at 4°C, the protein contents of supernatants were determined by BCA assay kit (Pierce, Thermo Fisher Scientific, Rockford, IL, USA). After that, equal volumes of supernatants and 29 SDS loading buffer were mixed and boiled for 5 min. Twenty micrograms of total proteins was subjected to SDS-PAGE and transferred onto a PVDF membrane. After blocking for 1 hr in room temperature, the membranes were incubated with ZEB1 antibody (Santa Cruz Biotechnology, Dallas, Texas, USA) overnight at 4°C. After washing four times, the membrane was incubated in the appropriate horseradish peroxidase-conjugated secondary antibodies at 37°C for 30 min. The protein bands were visualized using chemiluminescent reagents according to the manufacturer's instructions and quantified using an image analyser Quantity One System (Bio-Rad, Richmond, CA, USA).
Luciferase reporter assay. The 3 0 untranslated regions (3 0 -UTR) of human ZEB1 were amplified and ligated into the pmirGLO dualluciferase miRNA target expression vector (Promega, Beijing, China). Cells were transfected with pmirGLO-ZEB1 vector using Lipofectamine 2000 and then treated by 10 lg/ml GA for 24 hr. The activity of firefly luciferase was measured using a Dual-Luciferase Reporter Assay System (Promega) and normalized to that of Renilla luciferase.
Animal studies. All animal experiments were approved by the Committee on Ethical Use of Animals of The Second Affiliated Hospital of Xi'an Jiaotong University. Protocol 1: Twelve female nude mice (BALB/c, 4-6 weeks) were divided randomly into two groups (6 mice per group). A total of 5 9 10 6 A375/CDDP cells were injected subcutaneously into the right flank of all the nude mice. When the tumour had grown to 50 mm 3 , the mice were given an intraperitoneal injection of cisplatin (5 mg/kg) with or without an intraperitoneal injection of GA (1 mg/kg) every 3 days for 15 days. Protocol 2: Twelve female nude mice (BALB/c, 4-6 weeks) were divided randomly into two groups (6 mice per group). A total of 5 9 10 6 A375/CDDP cells were injected subcutaneously into the right flank of all the nude mice. When the tumour had grown to 50 mm 3 , the mice were given an intraperitoneal injection of cisplatin (5 mg/kg) with or without an intratumour injection of miR-199a-3p mimic (2 nmol) every 3 days for 15 days. Protocol 3: Twelve female nude mice (BALB/c, 4-6 weeks) were divided randomly into two groups (6 mice per group). A total of 5 9 10 6 A375/CDDP cells were injected subcutaneously into the right flank of all the nude mice. When the tumour had grown to 50 mm 3 , the mice were given an intraperitoneal injection of cisplatin (5 mg/kg) with or without an intratumour injection of LV-shZEB1 (2 nmol) every 3 days for 15 days. The tumours were monitored every 5 days, and tumour volumes were determined according to the following formula: 1/ 2 9 length 9 (width) 2. After 15 days, all mice were killed by euthanasia. Tumours were weighed and tumour tissues were collected for further determination. Statistical analysis. Data were expressed as the mean AE S.D., and experiments were carried out in triplicate. Student's t-test was used to assess the differences between two groups. Significant differences among more than three groups were analysed by one-way analysis of variance (ANOVA) followed by post hoc Duncan's multiple range tests. All statistical analysis was performed by GraphPad Prism Software (GraphPad Prism 5.0). A value of p < 0.05 was considered to be statistically significant.
Results
GA inhibits the malignancy in melanoma cells. In fig. 1A , we show that GA (1-10 lg/ml) concentrationdependently decreased the cell viability in melanoma A375 cells. In addition, the percentage of apoptotic cells in A375 cells was significantly increased by GA (1-10 lg/ml) in a concentration-dependent manner ( fig. 1B) . In the migration assay, 10 lg/ml GA significantly decreased the distance of cell migration ( fig. 1C,D) . In the transwell assay, 10 lg/ml GA significantly reduced the number of transwell cells ( fig. 1E,F) . The results demonstrated that GA inhibits the malignancy in melanoma cells.
GA increases cisplatin sensitivity in melanoma cells. We determined the relative sensitivity of A375 and A375/ CDDP cells to cisplatin. In fig. 2A , it is shown that A375/ CDDP cells were significantly resistant to cisplatin-induced cytotoxicity. A375 cells were treated with indicated concentrations of cisplatin in the presence of 1 lg/ml GA. The results show that GA significantly increased cisplatininduced cytotoxicity in A375 cells ( fig. 2B ). In parallel, A375/CDDP cells were also treated with indicated concentrations of cisplatin in the presence of 1 lg/ml GA. We also found that GA significantly increased cisplatin-induced cytotoxicity in A375/CDDP cells ( fig. 2C) . The results indicate that GA increased cisplatin sensitivity in melanoma cells.
Up-regulation of miR-199a-3p is involved in the inhibitory effect of GA on melanoma cell malignancy. We intended to explore the potential miRNA regulation in GAexhibited inhibition of melanoma. We found that miR-199a-3p expression was significantly increased by GA in a concentrationdependent manner (fig. 3A) . To test whether the up-regulation of miR-199a-3p was involved in the effect of GA, A375 cells were transfected with miR-199a-3p inhibitors and then incubated with 10 lg/ml GA. We showed that inhibition of miR-199a-3p significantly increased cell viability and decreased apoptosis in A375 cells ( fig. 3B,C) . Inhibition of miR-199a-3p notably inhibited the effect of GA on cell viability and apoptosis ( fig. 3B,C) . Moreover, miR-199a-3p inhibitors markedly promoted the migration ( fig. 3D,E) and invasion (fig. 3F,G) in A375 cells. miR-199a-3p inhibitors suppressed the effect of GA on migration ( fig. 3D,E)  and invasion (fig. 3F,G) in A375 cells. A375 cells were transfected with miR-199a-3p inhibitors and then treated by 5 lg/ml cisplatin with 1 lg/ml GA. A375/CDDP cells were transfected with miR-199a-3p inhibitors and then treated by 10 lg/ml cisplatin with 1 lg/ml GA. The results show that inhibition of miR199a-3p notably decreased cisplatin-induced cytotoxicity in both A375 and A375/CDDP cells ( fig. 3H,I ). Furthermore, inhibition of miR-199a-3p markedly prevented GA-induced increase in sensitivity to cisplatin ( fig. 3H,I ). These results indicate that miR-199a-3p is a negative regulator of the malignancy of melanoma and up-regulation of miR-199a-3p is involved in the inhibitory effect of GA on melanoma cell malignancy.
Up-regulation of miR-199a-3p inhibits melanoma cell malignancy. To further explore the biological role of miR-199a-3p in melanoma, we compared the expression of miR-199a-3p between melanoma tissue and cells and their controls. As shown in fig. 4A , the expression of miR-199a-3p was significantly lowered in melanoma tissues, as compared with benign nevi tissues. In addition, expression of miR-199a-3p was reduced in melanoma cell lines, including A375, WM35, SK-MEL-5 and SK-MEL-2 cells, as compared with HEMa-LP cells ( fig. 4B ). A375 cells were transfected with miR-199a-3p mimic, and the results show that up-regulation of miR-199a-3p significantly decreased cell viability ( fig. 4C ), increased apoptosis ( fig. 4D ) and increased migration ( fig. 4E) and invasion (fig. 4F) . The results indicate that down-regulation of miR-199a-3p is a characteristic of melanoma and up-regulation of miR-199a-3p inhibits melanoma cell malignancy. miR-199a-3p targets ZEB1 and regulates the malignancy through modulation of ZEB1 in A375 cells. Bioinformatics analysis reveals putative binding sequences of miR-199a-3p on zinc finger E-box binding homeobox (ZEB1) (fig. 5A ). The expression of miR-199a-3p and ZEB1 in melanoma tissues was negatively correlated (fig. 5B ). miR-199a-3p mimics significantly reduced the mRNA ( fig. 5C ) and protein ( fig. 5D) 5H) and invasion (fig. 5I) . The results indicate that miR-199a-3p targets ZEB1 and regulates the malignancy through modulation of ZEB1 in A375 cells. Down-regulation of ZEB1 is involved in the inhibitory effect of GA on melanoma cell malignancy. Next, we explored the role of ZEB1 in GA-exhibited inhibition of melanoma. We found that ZEB1 mRNA ( fig. 6A ) and protein ( fig. 6B ) expression was significantly decreased by GA in a concentration-dependent manner. To test whether the down-regulation of ZEB1 was involved in the effect of GA, A375 cells were transfected with LV-ZEB1 and then incubated with 10 lg/ml GA. We showed that up-regulation of ZEB1 significantly increased cell viability and decreased apoptosis in A375 cells ( fig. 6C and D) . Up-regulation of ZEB1 notably inhibited the effect of GA on cell viability and apoptosis ( fig. 6C,D) . Moreover, upregulation of ZEB1 markedly promoted the migration ( fig. 6E,F) and invasion ( fig. 6G,H ) in A375 cells. Up-regulation of ZEB1 suppressed the effect of GA on migration ( fig. 6E,F) and invasion ( fig. 6G,H ) in A375 cells. A375 cells were transfected with LV-ZEB1 and then treated by 5 lg/ml cisplatin with 1 lg/ml GA. A375/CDDP cells were transfected with LV-ZEB1 and then treated by 10 lg/ml cisplatin with 1 lg/ml GA. The results showed that up-regulation of ZEB1 notably decreased cisplatin-induced cytotoxicity in both A375 and A375/CDDP cells ( fig. 6I,J) . Furthermore, upregulation of ZEB1 markedly prevented GA-induced increase in sensitivity to cisplatin ( fig. 6I,J) . These results indicate that ZEB1 is a positive regulator of the malignancy of melanoma and down-regulation of ZEB1 is involved in the inhibitory effect of GA on melanoma cell malignancy.
Down-regulation of ZEB1 inhibits melanoma cell malignancy.
To further explore the biological role of ZEB1 in melanoma, we compared the expression of ZEB1 between melanoma tissue and cells and their controls. As shown in fig. 7A , the expression of ZEB1 was significantly increased in melanoma tissues, as compared with benign nevi tissues. In addition, the expression of ZEB1 was increased in melanoma cell lines, including A375, WM35, SK-MEL-5 and SK-MEL-2 cells, as compared with HEMa-LP cells ( fig. 7B ). A375 cells were transfected with LV- GA, miR-199a-3p up-regulation or ZEB1 down-regulation inhibits implanted melanoma in vivo.
To investigate the antitumour effect of GA, up-regulation of miR-199a-3p and down-regulation of ZEB1 on melanoma in vivo, we established an implanted tumour model in nude mice. A total of 5 9 10 6 A375/CDDP cells were injected subcutaneously into the right flank of all the nude mice. When the tumour had grown to 50 mm 3 , the mice were given an intraperitoneal injection of cisplatin (5 mg/kg) with or without an intraperitoneal injection of GA (1 mg/kg), or an intratumour injection of miR-199a-3p mimics (2 nmol) or an intratumour injection of LV-shZEB1 (2 nmol) every 3 days for 15 days. GA administration significantly decreased tumour volume ( fig. 8A) and weight (fig. 8B) , increased miR-199a-3p expression ( fig. 8C ) and decreased ZEB1 expression ( fig. 8C ) in the tumours. Moreover, GA administration significantly decreased BRAF, Akt1 and Akt2 expression in tumour tissues ( fig. 8D ), and these regulators are important for the regulation of proliferation and tumour development. The injection of miR-199a-3p . 8K ) in the tumour tissues. These results indicate that GA, miR-199a-3p up-regulation or ZEB1 downregulation inhibits implanted melanoma in vivo and that miR199a-3p-induced inhibition of ZEB1 is involved in GA-exhibited antitumour effect in melanoma ( fig. 9 ).
Discussion
Previous studies have identified the antitumour effects of GA in various types of cancers. Our findings and existing literature have confirmed the antitumour role of GA in melanoma [11, 26, 27] . However, the mechanism of GA-induced inhibition of melanoma is still not completely known. Further investigation of the mechanism of the antitumour effect of GA in melanoma will help explore new targets for the treatment of melanoma. In the present study, we focused on the miRNA regulation in pharmacological effect of GA against melanoma.
Consistent with our previous studies, we confirm the antitumour effect of GA in A375 melanoma cells. In addition, we found that low concentration of GA (1 lg/ml GA) significantly increased the cisplatin sensitivity in both cisplatin-sensitive and cisplatin-resistant A375 cells. Moreover, we found that miR-199a-3p expression was increased by GA and inhibition of miR-199a-3p not only increased the malignancy of melanoma cell but also prevented GA-induced inhibitory effect on melanoma cell. Furthermore, miR-199a-3p expression was decreased in melanoma tissues and cells, as compared with their controls. Up-regulation of miR-199a-3p expression inhibited the malignancy of melanoma both in vitro and in vivo. We suggest that miR-199a-3p functions as a tumour suppressor which mediates the antitumour effect of GA. Several studies have reported the biological role of miR-199a-3p in other types of cancer. Cui et al. [28] reported that miR-199a-3p enhanced cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Kinose et al. [29] found that miR-199a-3p displayed tumour suppressor functions in ovarian carcinoma. The overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy could be improved by miR-199a-3p [30] . In cholangiocarcinoma cells, miR-199a-3p enhances cisplatin sensitivity by inhibiting mTOR signalling pathway and expression of MDR1 [31] . miR-199a-3p also suppresses proliferation and invasion of prostate cancer cells by targeting Smad1 [32] . In combination with our findings in the current study, we suggest that miR199a-3p is an important tumour suppressor and up-regulation of miR-199a-3p is a critical step towards GA-induced antitumour effect in melanoma.
Bioinformatics analysis was performed to find the target of miR-199a-3p in the regulation of melanoma. We found that ZEB1 possessed potential binding sites with miR-199a-3p. miR-199a-3p exhibited inhibitory regulation of ZEB1. Up- regulation of ZEB1 could reverse miR-199a-3p mimics and GA-induced inhibition of melanoma. Moreover, ZEB1 expression in tumour tissues and cells was increased as compared with their controls. Down-regulation of ZEB1 inhibited melanoma both in vitro and in vivo, and the expression of ZEB1 and miR199a-3p in tumour tissues was negatively correlated. The results indicate that ZEB1 is the target of miR-199a-3p that mediates the antitumour effect of miR-199a-3p and GA. The transcriptional repressor ZEB1 is widely recognized as an important regulator of tumour development in various types of cancer. ZEB1 plays an oncogenic role that promotes tumour invasion, metastasis and resistance to chemo-and radiotherapy, in large part by mediating epithelial-to-mesenchymal transition (EMT) in cancer cells [33] . ZEB1 has been found to mediate the chemoresistant role of several lncRNAs and microRNAs [34] [35] [36] [37] . Based on these findings, we suggest that ZEB1 plays an oncogenic role in melanoma and down-regulation of ZEB1 mediates the antitumour effect of GA and miR-199a-3p in melanoma.
In conclusion, we have identified the important roles of miR-199a-3p and ZEB1 in melanoma and elucidated the tumour suppressor function of miR-199a-3p through inhibition of ZEB1. The results demonstrate that GA inhibits melanoma through miR-199a-3p-ZEB1 signalling. The results highlight the importance of miR-199a-3p-ZEB1 signalling in antitumour effect of GA in malignant melanoma and provide novel targets for the chemotherapy of melanoma.
